文献速递泌尿生殖与妇科肿瘤放疗

局限性前列腺癌剂量递增外照射放疗对生活质量的影响:前瞻性随机3期临床试验NRG/RTOG 0126结果

Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-01-01

NRG/RTOG 0126 3期试验将1532例前列腺癌患者随机分为79.2 Gy/44次与70.2 Gy/39次两组,比较患者报告结局(PRO)。可分析数据显示,12个月时单问题评估的勃起功能障碍两组无显著差异(标准剂量组38.1% vs 剂量递增组49.7%,P=.051),治疗臂对所有收集领域的PRO指标均无显著影响;PRO数据收集依从性低于预期。

要点

  • 剂量递增组79.2 Gy/44次与标准剂量组70.2 Gy/39次相比,12个月勃起功能障碍无显著差异(38.1% vs 49.7%,P=.051)。
  • 治疗臂(70.2 Gy vs 79.2 Gy)对所有收集领域的PRO指标均无显著影响。
  • 本3期试验中PRO数据收集依从性低于预期。

核心结论

  • 在本3期试验的可分析数据中,剂量递增外照射放疗似乎未对多个前瞻性收集领域的PRO造成损害。
  • 这些数据在存在局限性的情况下增进了对前列腺癌外照射放疗剂量递增影响的理解,并说明PRO数据收集面临的挑战。

研究设计与样本

  • 3期随机临床试验NRG/RTOG 0126于2002年3月至2008年8月随机入组1532例前列腺癌患者,比较79.2 Gy/44次与70.2 Gy/39次外照射放疗。
  • PRO工具包括国际勃起功能指数问卷(IIEF)、排尿变化所致功能改变(FACE)和Spitzer生活质量指数(SQLI);IIEF于入组前及6、12、24个月收集,FACE和SQLI于入组前及3、6、12、18、24个月收集。
  • 同时分析外照射放疗剂量对正常结构(阴茎球、直肠和膀胱)的影响,采用混合效应模型分析时间趋势。

主要发现

  • 1144例完成基线IIEF,其中56%、64%、61%分别在6、12、24个月完成IIEF。
  • 1123例完成基线FACE评分,其中50%、61%、73%、61%、65%分别在3、6、12、18、24个月完成FACE全部15个条目。
  • 12个月时基于单问题评估的勃起功能障碍两组无显著差异:标准剂量放疗组38.1% vs 剂量递增放疗组49.7%(P=.051)。
  • 治疗臂(70.2 Gy vs 79.2 Gy)对所有收集领域的任何PRO指标均无显著影响。
  • 综合剂量学分析显示对区域危及器官存在多个显著差异。

局限性

  • 本3期试验中PRO数据收集依从性低于预期。
  • 结论指出这些数据存在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: External beam radiation therapy (EBRT) dose escalation has been tested in multiple prospective trials. However, the impact on patient reported outcomes (PROs) associated with higher doses of EBRT remain poorly understood. We sought to assess the differences in PROs between men treated with a dose of 70.2 Gy versus 79.2 Gy of EBRT for prostate cancer. METHODS AND MATERIALS: The phase 3 clinical trial RTOG 0126 randomized 1532 patients with prostate cancer between March 2002 and August 2008 to 79.2 Gy over 44 fractions versus 70.2 Gy over 39 fractions. Eligible patients participated in the PRO data collection. PROs completed included the International Index of Erectile Function Questionnaire (IIEF), Functional Alterations due to Changes in Elimination (FACE), and the Spitzer Quality of Life Index (SQLI). The timepoints for the IIEF were collected pre-entry and at 6, 12, and 24 months. The FACE and SQLI were collected pre-entry and at 3, 6, 12, 18, and 24 months. The impact of EBRT dose to normal structures (penile bulb, rectum, and bladder) on PROs was also examined. Mixed effects models were used to analyze trends across time. RESULTS: In total, 1144 patients completed baseline IIEF forms and of these, 56%, 64%, and 61% completed the IIEF at 6, 12, and 24 months, respectively; 1123 patients completed the FACE score at baseline and 50%, 61%, 73%, 61%, and 65% completed all 15 items for the FACE metric at timepoints of 3, 6, 12, 18, and 24 months, respectively. Erectile dysfunction at 12 months based on the single question was not significantly different between arms (38.1% for the standard dose radiation therapy arm vs 49.7% for the dose escalated radiation therapy arm; P = .051). Treatment arm (70.2 vs 79.2) had no significant impact on any PRO metrics measured across all collected domains. Comprehensive dosimetric analyses are presented and reveal multiple significant differences to regional organs at risk. CONCLUSIONS: Compliance with PRO data collection was lower than anticipated in this phase 3 trial. Examining the available data, dose escalated EBRT did not appear to be associated with any detriment to PROs across numerous prospectively collected domains. These data, notwithstanding limitations, add to our understanding of the implications of EBRT dose escalation in prostate cancer. Furthermore, these results illustrate challenges associated with PRO data collection.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hall WA, Deshmukh S, Bruner DW, et al. Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126. Int J Radiat Oncol Biol Phys. 2022. PMID: 34919884. doi:10.1016/j.ijrobp.2021.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。